DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices

Information source: French National Agency for Research on AIDS and Viral Hepatitis
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C; Substance Dependence; Methadone

Intervention: Methadone (Drug)

Phase: Phase 3

Status: Not yet recruiting

Sponsored by: French National Agency for Research on AIDS and Viral Hepatitis

Official(s) and/or principal investigator(s):
Alain Morel, MD, Principal Investigator, Affiliation: CSST Le trait d'union, 154 rue du vieux pont de Sèvres, 92100 Boulogne, France
Patrizia Carrieri, PHD, Study Director, Affiliation: ORS PACA - INSERM-IRD UMR912, 23, rue Stanislas Torrents, 13006 Marseille

Summary

The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.

This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in Intravenous drug users.

Clinical Details

Official title: Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville

Study design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: prevalence of daily injectors after one year of treatment will be compared between arms.

Secondary outcome:

- prevalence of other addictive behaviours

adherence to treatment

improvement in quality of life, psychiatric comorbidities, social insertion, reduction in criminal acts

cost-effectiveness

surveillance of severe adverse events and overdose cases in each arm

Detailed description: The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.

This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in Intravenous drug users.

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18 to 70 years patients needing methadone for their opioid dependence who are either

naives of methadone treatment (prescribed) since at least 1 month

- need to switch from buprenorphine to methadone treatment

- negative test for pregnancy

Exclusion Criteria:

- co-dependent on alcohol and benzodiazepines,

- inmates,

- pregnant women,

- individual in irregular situation or who cannot be joined by phone.

Locations and Contacts

CSST Le trait d'union, Boulogne 92100, France
Additional Information

Starting date: September 2008
Ending date: September 2010
Last updated: June 18, 2008

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009